US-based eye care firm Alcon Laboratories, Inc. has announced the acquisition of a majority stake in Aurion Biotech, Inc., a clinical-stage cell therapy specialist focused on eye diseases. This strategic move aims to enhance Alcon’s portfolio in innovative ophthalmic treatments.
Aurion Bio’s Leading Therapy
Aurion Bio’s flagship product, AURN001, is an allogeneic cell therapy targeting secondary corneal edema caused by corneal endothelial disease. The therapy has been recognized with Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation in the US. It has completed patient enrollment and dosing in the Phase I/II CLARA study, demonstrating promising potential.
Future Development Plans
Operating as a separate entity with full support from Alcon, Aurion Bio is poised to advance AURN001 into Phase III trials later this year. This progression underscores the commitment to addressing unmet medical needs in ophthalmology through cutting-edge cell therapies.-Fineline Info & Tech
Leave a Reply